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Background: Whether portal hypertension (PHT) is an appropriate contraindication for hepatic resection (HR) in
hepatocellular carcinoma (HCC) patient is still under debate.
Aims: Our aim was to assess the impact of clinically significant PHT on postoperative complication and prognosis in
HCC patients who undergo HR.
Methods: Two hundred and nine HCC patients who underwent HR as the initial treatment were divided into two
groups according to the presence (n = 102) or absence (n = 107) of clinically significant PHT. Propensity score
matching (PSM) analysis was used to compare postoperative outcomes and survival.
Results: Before PSM, PHT patients had higher rates of postoperative complication (43.1% vs. 23.4%; P = 0.002) and
liver decompensation (37.3% vs. 17.8%; P = 0.002) with similar rates of recurrence-free survival (RFS; P = 0.369) and
overall survival (OS; P = 0.205) compared with that of non-PHT patients. However, repeat analysis following PSM
revealed similar rates of postoperative complication (32.2% vs. 39.0%; P = 0.442), liver decompensation (25.4% vs.
32.2%; P = 0.416), RFS (P = 0.481) and OS (P = 0.417; 59 patients in each group). Presence of PHT was not associated
with complication by logistic regression analysis, or with overall survival by Cox regression analysis.
Conclusions: The presence of clinically significant PHT had no impact on postoperative complication and
prognosis, and should not be regarded as a contraindication for HR in HCC patients.
Keywords: Hepatocellular carcinoma, Hepatic resection, Portal hypertension, Complication, PrognosisBackground
Liver cancer is the sixth most common cancer, the third
cause of cancer-related death and accounts for 7% of all
cancers [1]. Curable treatments for hepatocellular carcin-
oma (HCC) include liver transplantation, hepatic resection
(HR) and percutaneous approaches. Portal hypertension
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unless otherwise stated.HCC patients according to the 2001 European Association
for Study of Liver (EASL). These observations are based
on the findings of a study [2] involving 29 patients in 1996
which concluded that PHT, defined as a hepatic venous
pressure gradient (HVPG) ≥ 10 mmHg, was a predictor of
postoperative liver decompensation [2], and another study
in 1999 showing that Child-Pugh A patients with PHT
have poor survival after HR [3]. Although this conclusion
is supported by subsequent studies [4-7], contradictory re-
ports have also been published indicating that HR is safe
and beneficial in well-selected HCC patients with PHT be-
cause postoperative outcomes and survival are similar, re-
gardless of the presence or absence of clinically significant
of PHT [4,8-11].is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
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HCC patients after HR remains a highly debated topic.
Nevertheless, the 2012 EASL-EORTC Clinical Practice
Guidelines still advise against HR as the first-line treatment
option for HCC patients with PHT, defined as hepatic ven-
ous pressure gradient ≥ 10 mmHg or with surrogates of
portal hypertension, defined as esophageal varices, or
splenomegaly with platelet count < 100,000/mm3 [12].
We therefore conducted a retrospective study involv-
ing HCC patients who underwent HR as the initial treat-
ment to assess the role of clinically significant PHT in
HCC patients after HR. Propensity score matching was
used in the analysis to reduce bias in patient selection




We retrospectively collected data from 1542 patients
who underwent HR as the initial treatment for HCC
from January 2003 to December 2008 at Sun Yat-sen
University Cancer Center in China. The diagnosis of
HCC was confirmed postoperatively by pathological
investigation.
HVPG over 10 mmHg was regarded as the gold diag-
nosis criteria of PHT. It is not, however, routinely used
in clinical practice for its invasiveness. Studies show
esophageal varices, low platelet count, low white blood
cell count [13], splenomegaly, a portal vein diameter on
ultrasound (US) ≥13 mm, a high Child-Pugh score, low
prothrombin activity, spider angiomas, and a low platelet
to spleen ratio are associated with clinically significant
PHT [14]. Therefore, portal hypertension was indirectly
defined, which incorporated the BCLC criteria [15] and
the Italian Programme on Liver Cirrhosis [16, 17] if two
or more of the following criteria were met: 1) Platelet
count < 100 × 109/l and/or white blood cell count < 4 ×
109/l three times in succession, 2) Splenomegaly (spleen
thickness > 4.5 cm via ultrasound or major diameter >
10 cm via CT/MR), 3) Portal vein width > 14 mm or
spleen vein width > 10 mm via ultrasound, and 4)
Esophageal varices via endoscopy or CT/MR.
Of the 1542 patients who underwent HR as initial
treatment for HCC, 231 patients were diagnosed with
PHT. We subsequently excluded 34 of the 231 PHT pa-
tients for hepatic major vessel invasion, 12 for second
primary tumors, and 75 for incomplete preoperative
clinical data. This left 110 patients in the PHT group eli-
gible for analysis and 110 patients without PHT were
randomly selected from the remaining 1280 patients as
the control group. There were seven patients in the
PHT group and three patients in the non-PHT group
lost to follow-up. The study ultimately enrolled 209 pa-
tients, with 102 in the PHT group and 107 in the non-PHT group (Figure 1). All the recruited patients pro-
vided written informed consent before examination and
resection. The study protocol was approved by the Eth-
ics Committee of Sun Yat-Sen University Cancer Center
and conformed to the ethical guidelines of the Helsinki
Declaration.
Methods
The hepatic resection strategy was detailed in our previ-
ous report [18]. Briefly, we developed a surgical plan ac-
cording to tumor extent evaluated by preoperative
imaging and liver function evaluated by blood biochem-
istry, Child-Pugh grading, and ICGR15 level. Intraopera-
tive ultrasound was applied to guarantee complete
tumor resection and to reduce major vessel injury. A
Cavitron ultrasonic surgical aspirator (CUSA) was used
to dissect parenchyma. To decrease intraoperative blood
loss, we applied the intermittent Pringle maneuver
method for the majority of hepatic resections and low-
ered central venous pressure to 2–4 mmHg routinely.
We used blood transfusions to maintain hemoglobin at
least 80–90 g/l according to the degree of bleeding and
the preoperative hemoglobin level.
Postoperative complications in the first 90 days were
recorded and assessed by the Clavien-Dindo classifica-
tion at grades ranging from one to five, with higher
grades indicating greater severity [19]. We defined
postoperative liver decompensation as the presence of
refractory ascites and edema, hepatic encephalopathy,
jaundice with total bilirubin levels above 50 μmol/l [20],
renal impairment, and alteration of coagulation factors
(INR above 1.50) requiring fresh transfusion. The obser-
vation and grading of complications were reviewed inde-
pendently by two of the authors, and any disagreements
were resolved by consensus.
After surgery, all patients were followed up monthly in
the first 3 months, every three3 months in the first
2 years and every 3–6 months thereafter. The follow-up
strategy was more intensive for patients with recurrence
or metastases. Recurrence was observed by measure-
ments of serum alpha-fetoprotein level combined with
ultrasound, computed tomography or magnetic reson-
ance imaging. The treatment strategy for recurrence in-
cluded repeat resection/ablation for patients with three
lesions or fewer and transhepatic arterial chemotherapy
and embolization (TACE) or sorafenib for patients with
more than three lesions. Overall survival was calculated
from the time of HR to death or last follow-up until
September 2013.
Statistical analysis
Data were summarized as median for continuous vari-
able and number/prevalence for categorical variable.
Continuous variables were compared by the independent
Figure 1 Flow chart.
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ate. Binary and ordinal categorical variable were com-
pared by the Chi-square test and Kruskal-Wallis test,
respectively. Logistic regression with stepwise manner
(entry criterion P = 0.05 and removal criterion P = 0.1)
was used to explore independent prognostic factors of
postoperative outcome. Recurrence-free survival (RFS)
and overall survival (OS) were assessed by the Kaplan-
Meier method using the log-rank test. Cox proportional
hazards model in a stepwise manner (entry criterion P =
0.05 and removal criterion P = 0.1) was used in multivari-
ate analysis to explore independent prognostic factors of
overall survival.
Variables with statistically significant differences be-
tween groups might have impact on the postoperative
outcomes. Therefore we applied propensity score match-
ing (PSM) analysis [21, 22] to minimize the influence of
selection bias and potential confounding variables
between groups. Potential covariables included in PSM
included age, alanine aminotransferase, aspartate amino-
transferase, hemoglobin, albumin, total bilirubin, creatin-
ine, prothrombin time, activated partial thromboplastin
time, INR, Child-Pugh score, MELD score, extent of
hepatectomy, tumor size, and tumor number. PHT re-
lated variables were excluded, including white blood cell
and platelet count. A one-to-one nearest neighbor
matching algorithm was applied with a caliper of 0.2
[23] and without replacement. After matching, 118 pa-
tients were included in further analysis (59 in each
group). Standardized mean differences were also re-
ported for all variables. Statistical analysis was performed
using SPSS (IBM SPSS Statistics for Windows, Version
20.0. IBM Corp., Armonk, NY) and Propensity ScoreMatching for SPSS, version 1.0 (Felix Thoemmes,
Cornell University/University of Tübingen). P < 0.05 was
considered as statistically significant.Results
The baseline characteristics of demographic and clinical
variables in both groups are described in Table 1. The
most frequent etiology was chronic hepatitis B virus
(HBV) in both the PHT and non-PHT groups (93.1% vs.
94.4%). In particular, patients in the PHT group have
higher total bilirubin levels (19.5 vs. 14.6 μmol/l; P < 0.001),
higher INR values (1.1 vs. 1.0; P = 0.009), longer prothrom-
bin time (14.2 vs. 13.1; P < 0.001), longer activated partial
thromboplastin time (54.1 vs. 35.4; P < 0.001), lower cre-
atinine levels (79.7 vs. 86.2; P = 0.009), lower serum
albumin levels (40.7 vs. 42.6 g/l; P = 0.006), higher Child-
Pugh score (5.3 vs. 5.1; P < 0.001) and higher MELD score
(8.8 vs. 7.9; P < 0.001). Patients with PHT have smaller tu-
mors (5.3 vs. 6.5; P = 0.006). Both groups have a similar
number of tumors (P = 0.575), while patients with PHT
received less extensive resection.
As shown in Table 2, patients in the PHT group have
higher liver decompensation rates (37.3% vs. 17.8%; P =
0.002), higher postoperative complication rate (43.1% vs.
23.4%; P = 0.002) and stayed longer in hospital (12.9 days
vs.12.1 days; P < 0.001), compared with those of the non-
PHT group. However, the distribution of severity of
postoperative complication in both groups was similar
(P = 0.818); seven deaths occurred within 90 days as a
result of liver failure, five in the PHT group and two in
the non-PHT group. The mortality rate was similar
(4.90% vs. 1.87%; P = 0.271).
Table 1 Baseline clinical and intraoperative characteristics of patients before and after PSM
Variable Before PSM After PSM
non-PHT (n = 107) PHT (n = 102) P d non-PHT (n = 59) PHT (n = 59) P d
Age (yr) 48.5 ± 11.4 49.4 ± 11.2 0.468 −0.080 48.7 ± 12.1 49.1 ± 10.8 0.561 −0.035
>65:<65 11:96 12:90 0.732 −0.083 7:46 5:54 0.542 0.274
Gender (male: female) 91:16 85:17 0.734 0.071 51/8 49/10 0.609 0.145
HBV/No-HBV 101/6 95/7 0.707 0.119 55/4 53/6 0.509 0.244
ALB (g/L) 42.6 ± 4.2 40.7 ± 4.9 0.006 0.417 42.1 ± 4.3 42.1 ± 3.9 0.802 −0.001
TBil (μmol/L) 14.6 ± 5.4 19.5 ± 7.3 <0.001 −0.766 16.6 ± 5.6 17.3 ± 5.8 0.611 −0.123
ALT (U/L) 45.2 ± 24.8 50.6 ± 36.5 0.254 −0.174 50.7 ± 28.5 47.2 ± 23.2 0.891 0.135
AST (U/L) 48.5 ± 25.3 51.1 ± 38.2 0.803 −0.081 48.4 ± 19.0 47.9 ± 22.3 0.675 0.024
WBC (109/L) 6.4 ± 1.6 5.2 ± 2.2 <0.001 0.626 6.4 ± 1.8 5.1 ± 2.1 <0.001 0.665
RBC (1012/L) 4.6 ± 0.7 4.5 ± 0.7 0.402 0.143 4.5 ± 0.7 4.6 ± 0.8 0.515 −0.133
Hemoglobin (g/L) 138.2 ± 19.5 139.2 ± 19.1 0.776 −0.052 138.3 ± 17.8 141.3 ± 19.2 0.385 −0.162
Thrombocyte (109 /L) 189.4 ± 66.6 96.4 ± 42.4 <0.001 1.657 171.4 ± 63.1 97.9 ± 44.6 <0.001 1.3452
Creatinine (μmol/L) 86.2 ± 19.2 79.7 ± 18.9 0.009 0.341 83.6 ± 19.2 80.7 ± 20.4 0.376 0.146
BUN (mmol/L) 5.1 ± 1.2 7.60 ± 2.6 0.663 −1.245 5.2 ± 1.2 5.1 ± 1.4 0.376 0.077
PT (sec) 13.1 ± 1.2 14.2 ± 1.2 <0.001 −0.917 13.7 ± 0.9 13.8 ± 0.9 0.751 −0.111
APTT (sec) 35.4 ± 5.9 54.1 ± 38.6 <0.001 −0.685 37.1 ± 5.6 37.3 ± 6.2 0.946 −0.034
INR 1.00 ± 0.3 1.1 ± 0.1 <0.001 −0.443 1.1 ± 0.1 1.1 ± 0.1 0.530 0.001
Child-Pugh classification (A/B) 105/2 99/3 0.957 0.256 57/2 59/0 0.476 -
MELD score 7.9 ± 1.4 8.8 ± 1.9 <0.001 −0.541 8.2 ± 1.5 8.3 ± 1.6 0.825 −0.065
MELD classification (<9:9–10:>10) 84:15:8 57:20:25 <0.001 −0.547 42:9:8 41:8:10 0.776
Size of the tumor (cm) 6.5 ± 3.3 5.3 ± 3.1 0.006 0.375 5.7 ± 3.2 5.5 ± 2.9 0.912 0.066
Vascular invasion(pre: abs) 7:100 15:87 0.055 −0.497 3:56 9:50 0.068 −0.668
Adjacent tissues invasion (pre: abs) 17:90 12:90 0.389 0.192 8:51 9:50 0.793 −0.076
Lymphatic metastasis (pre: abs) 2:105 1:101 1.000 0.361 0 1:58 1.000 -
Number of tumor (1:2:>2) 77:15:15 71:11:20 0.575 −0.104 42:7:10 41:8:10 0.870 −0.022
Extent of hepatectomy (1:2:>2) 46:36:25 55:36:11 0.034 0.319 29:20:10 35:16:8 0.289 0.185
Intraoperative heamorrhage > 400 ml 25 28 0.497 −0.119 8 16 0.067 −0.476
Intraoperative transfusion 20 24 0.391 −0.161 6 11 0.190 −0.389
Pringle maneuver 85 76 0.397 0.154 50 46 0.344 0.249
Continuous variables are reported in mean and standard deviation.
d indicates standardized mean differences.
Table 2 Postoperative outcomes before and after PSM
Variables Before PSM After PSM
non-PHT (n = 107) PHT (n = 102) P non-PHT (n = 59) PHT (n = 59) P
Hospital stay (days) 12.1 ± 5.3 12.9 ± 3.9 <0.001 12.6 ± 6.1 12.8 ± 4.2 0.082
Liver decompensation 19(17.8%) 38(37.3%) 0.002 15(25.4%) 19(32.2%) 0.416
Complication 25(23.4%) 44(43.1%) 0.002 19(32.2%) 23(39.0%) 0.442
Clavien-Dindo Classification 0.818 0.929
Grade 1 17(15.7%) 31(30.4%) 12(20.3%) 15(25.4%)
Grade 2 2(1.9) 5(4.9%) 2(3.4%) 3(5.1%)
Grade 3 3(2.8%) 3(2.9%) 3(5.1%) 2(3.4%)
Grade 4 1(0.9%) 0 1(1.7%) 0
Grade 5 2(1.9%) 5(4.9%) 1(1.7%) 3(5.1%)
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complications occurred more frequently in patients with
PHT (P = 0.003), age > 65 (P = 0.043), requiring intraop-
erative transfusion (P = 0.021), INR > 1.20 (P = 0.044) and
with a greater number of tumors (P = 0.031). Liver
decompensation occurred more frequently in patients
with PHT (P = 0.002), intraoperative hemorrhage > 400 ml
(P = 0.050), requiring intraoperative transfusion (P =
0.003), INR > 1.2 (P = 0.017) and with a greater number of
tumors (P = 0.018).
Multivariate analysis showed that the presence of PHT
(Odds ratio: 2.415; 95% Confidence interval: 1.307–
4.463; P = 0.050), age > 65 (OR: 2.683; 95%CI: 1.069–
6.733; P = 0.036) and multiple tumor number (OR: 1.494;
95%CI: 1.013–2.203; P = 0.043) were significant predictors
for postoperative complication. The presence of PHT
(OR: 2.650; 95%CI: 1.375–5.110; P = 0.004), intraoperative
transfusion (OR: 2.687; 95%CI: 1.293–5.584; P = 0.008)
and greater number of tumors (OR: 1.495; 95% CI: 1.003–
2.229; P = 0.048) were significant predictors for liver
decompensation. Both groups had similar RFS rates (P =
0.369) with a median recurrence-free time of 23.57 months
and similar OS rates (P = 0.205) with a median follow-up




Age > 65y (Yes : No) 52.2% : 30.6% 0.043 50.0%
Gender (Male : Female) 31.8% : 39.4% 0.397 35.6%
Etiology of cirrhosis (HBV : Non-HBV) 32.7% : 38.5% 0.667 34.3%
ALB (<35 : >35) 47.1% : 31.8% 0.205 50.0%
TBIL (<34.2 : >34.2) 33.3% : 0 0.999 35.6%
INR (<1.2 : >1.2) 30.4% : 50.0% 0.044 34.3%
Child-Pugh classification (A : B) 32.4% : 60.0% 0.217 35.3%




Size of tumor (<5 : >5) 33.9% : 32.0% 0.763 30.0%
Vascular invasion (Yes : No) 36.4% : 32.6% 0.724 42.9%
Adjacent tissues invasion (Yes : No) 31.0% : 33.3% 0.807 35.3%
Lymphatic metastasis (Yes : No) 0 : 33.5% 0.999 0 : 35




PHT (Yes : No) 43.1% : 23.4% 0.003 39.0%




Intraoperative hemorrhage >400 ml
(Yes : No)
41.5% : 30.1% 0.130 54.2%
Intraoperative Transfusion (Yes : No) 47.7% : 29.1% 0.021 58.8%
Pringle maneuver (Yes : No) 33.5% : 31.2% 0.767 35.4%82%, 59%, 46% in the PHT group and 86%, 65%, 50% in
the non-PHT group, respectively. After recurrence, 19
patients underwent resection, 36 patients underwent per-
cutaneous microwave coagulation or radiofrequency abla-
tion, 62 patients received TACE and four patients received
sorafenib treatment.
Results after propensity score matching
The demographic and clinical characteristics were gener-
ally similar in both groups (59 in the PHT group and 59
in the non-PHT group) after covariates had been ad-
justed by PSM (Table 1). The standardized difference in
means and individual propensity scores of patients is
shown in Figures 2 and 3. Variables that were unevenly
distributed before PMS included age > 65 (P = 0.542),
INR (P = 0.530), number of tumors (P = 0.870) and intra-
operative transfusion (P = 0.067).
The postoperative outcome after PSM matching is shown
in Table 2. No significant difference in outcome was found
between the two groups. Specifically, both groups had a
similar length of hospital stay (12.64 vs. 12.83; P = 0.082),
liver decompensation rate (25.4% vs. 32.2%; P = 0.416),
postoperative complication rate (32.2% vs. 39.0%; P = 0.442)
and distribution of severity of complication (P = 0.929).tive complication and liver decompensation
Liver decompensation
PSM Before PSM After PSM
lence P Prevalence P Prevalence P
: 34.0% 0.278 34.8% : 26.3% 0.394 25.0% : 29.2% 0.759
: 38.9% 0.751 27.8% : 24.2% 0.670 31.0% : 16.7% 0.226
: 50.0% 0.326 28.1% : 15.4% 0.331 29.6% : 20.0% 0.524
: 34.8% 0.456 41.2% : 26.0% 0.186 33.3% : 28.6% 0.802
: 0 0.999 27.5% : 0 0.999 0 : 0 -
: 50.0% 0.326 24.3% : 46.4% 0.017 26.9% : 50.0% 0.134
: 50.0% 0.672 40.0% : 27.0% 0.523 0 : 29.3% 0.999
: 47.1% : 0.460 24.1% : 40.0% :
27.3%
0.359 27.7% : 41.2% :
22.2%
0.941
: 43.8% 0.127 25.0% : 29.9% 0.428 20.0% : 41.7% 0.012
: 34.6% 0.547 31.8% : 26.7% 0.613 35.7% : 27.9% 0.545
: 35.6% 0.978 31.0% : 26.7% 0.624 35.3% : 27.7% 0.525
.9% 1.000 0 : 27.7% 0.999 0% : 29.1% 1.000
: 53.3% : 0.111 23.0% : 30.8% :
42.9%
0.018 25.3% : 33.3% :
40.0%
0.176
: 32.2% 0.442 37.3% : 17.8% 0.002 32.2% : 25.4% 0.417
: 44.4% : 0.099 23.8% : 31.9% :
27.8%
0.439 21.9% : 36.1% :
38.9%
0.088
: 30.9% 0.037 37.7% : 23.7% 0.050 50.0% : 23.4% 0.013
: 31.7% 0.036 45.5% : 22.4% 0.003 52.9% : 24.8% 0.022
: 36.4% 0.933 28.0% : 25.0% 0.687 29.2% : 27.3% 0.860
Figure 2 Parallel line plot of the standardized difference in means before and after PSM in HCC patients with and without PHT. As the
standardized difference in means was reduced, covariate balance was improved in the matched samples.
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operative liver failure, three in the PHT group and one in
the non-PHT group with similar mortality rate (5.08% vs.
1.69%; P = 0.619).
Univariate analysis in matched patients showed that
postoperative complication and liver decompensation oc-
curred more frequently in patients with intraoperative
hemorrhage more than 400 ml (P = 0.037 and P = 0.013,
respectively) and requiring intraoperative transfusion (P =
0.036 and P = 0.022, respectively; Table 3).
Logistic regression identified intraoperative transfusion
(OR: 3.080; 95%CI: 1.075–8.828; P = 0.036) and intraop-
erative hemorrhage of more than 400 ml (OR: 3.273;
95%CI: 1.289–8.310; P = 0.013) as independent predict-
ive factors of postoperative complication and liver
decompensation, respectively. Both groups had similar
RFS rates (P = 0.481) with a median RFS time of
23.07 months and similar OS rates (P = 0.417) with a
median follow-up of 57.57 months. OS rates of 1, 3, and
5 years are 83%, 59%, 48% in the PHT group and 85%,
67%, 50% in the non-PHT group (Figure 4). Multivariate
Cox proportional hazard regression (Table 4) identified
MELD score (RR: 2.113; 95%CI: 1.242-3.593, P = 0.006),
number of tumors (RR: 2.020, 95%CI: 1.192-3.424, P =
0.009), vascular invasion (RR: 2.289, 95%CI: 1.137-
4.612, P = 0.020), adjacent tissues invasion (RR: 2.549,
95%CI: 1.372-4.735, P = 0.003) and intraoperative
hemorrhage > 400 ml (RR: 1.849, 95%CI: 1.027-3.330, P
= 0.041) as predictors for death. Importantly, PHT wasnot identified as a predictor for death in the post-PSM
Cox regression analysis.
Characteristics and outcome of unmatched patients
Forty-eight patients were excluded from the non-PHT
group by PSM. These patients had a mean tumor size of
7.29 ± 3.33 cm, a CTP score of 5.04 ± 0.20, and a MELD
score of 7.54 ± 1.14. There were five grade I complications,
no grade II, III or IV complications, and one grade V
complication, and the 1, 3, and 5 year survival rates were
88%, 63% and 49%, respectively. Forty-three patients were
excluded from the PHT group by PSM. The excluded pa-
tients had a mean tumor size of 5.20 ± 3.48 cm, a CTP
score of 5.54 ± 0.71 and a MELD score of 9.61 ± 1.97.
Grade I, II, III, IV, and V complications occurred in 16, 2,
1, 0 and 2 cases, respectively, and the 1-, 3- and 5-year
survival rates were 80%, 57% and 43%, respectively.
Discussion
In 2001, the EASL (European Association for Study of
Liver) concluded that PHT was a contraindication for
HR [24] based on a 29-case cohort in which HCC pa-
tients had higher risk of hepatic decompensation(73.3%
vs. 0%,P < 0.0002)when PHT was diagnosed by HVPG ≥
10 mmHg [2]. Further evidence of the impact of PHT
on long-term survival, was taken from a later study
which found that HVPG ≥ 10 mmHg or clinically signifi-
cant PHT was an independent prognostic factor [3].
These results are supported by multiple regional studies
Figure 3 Dot plot of the propensity scores of patients in the PHT and the non-PHT groups showing individual units in the dataset and whether
they were matched or discarded.
He et al. BMC Cancer  (2015) 15:263 Page 7 of 11over the past decade suggesting that HCC patients indir-
ectly diagnosed with PHT [5-7,11] or directly diagnosed
by HVPG [25,26] more frequently suffer from severe
postoperative hepatic decompensation and have shorter
survival. Although HVPG has a robust prognostic value
[25,26], it is not routinely applied in practice because of
invasiveness, high cost and patient discomfort. As a re-
sult, the EASL-EORTC clinical practice guidelines also
suggest surrogate measurements for the diagnosis of
portal hypertension, including platelet count below
100,000/mm3 associated with splenomegaly and
oesophageal varices [12].
However, several other large studies [4,8-11] reported
no significant difference in postoperative outcomes be-
tween PHT and non-PHT HCC patients when PHT is
diagnosed with these clinical criteria. In Child-Pugh
class A patients, no difference was found in postopera-
tive mortality, morbidity [8] and survival [27] between
the PHT and the non-PHT group. Similarly Cucchetti
et al. reported that portal hypertension had no effect on
postoperative outcome and survival as long as other
prognostic variables were evenly distributed between
both groups [4]. Additionally, Child-Pugh A or B pa-
tients with esophageal varices have a significantly higher5-year overall survival rate and a similar postoperative
complication rate when compared with patients without
esophageal varices [9]. A further study of 434 patients
found that PHT was not a prognostic factor with regard
to the overall survival, and concluded that resection for
HCC may also be applied to patients with PHT [10].
These reports, therefore, strongly suggest that if the liver
function of HCC patients is well-preserved, postopera-
tive outcome and survival is similar regardless of pres-
ence or absence of clinically significant PHT.
In this retrospective study, the presence of clinically
significant PHT was not found to be a predictor of post-
operative complication or liver decompensation in uni-
variate and multivariate analysis when other variables
were evenly distributed by PSM. The inferior postopera-
tive outcome of PHT patients before matching may be
explained by poor preoperative liver function, which
may exaggerate the impact of PHT on HCC patients.
After matching, both groups show similar demographic
and clinical characteristics, suggesting that PSM effi-
ciently eliminates covariates and minimizes their
confounding effect, thus resulting in the similar intraop-
erative and postoperative outcomes. Specifically, there
was no difference in the frequency or distribution of
Figure 4 Kaplan-Meier survival curves in HCC patients who underwent HR. (A) and (B) show recurrence-free survival in the PHT and non-PHT
groups before and after PSM, respectively. (C) and (D) show overall survival between the PHT and the non-PHT groups before and after
PSM, respectively.
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variables affecting the postoperative complication and
liver decompensation rates were intraoperative transfu-
sion and intraoperative hemorrhage of more than
400 ml, respectively. This observation is supported by
previous studies [28-30]. HCC patients with cirrhosis are
more likely to have coagulopathy, leading to a higher
risk of hemorrhage and intraoperative transfusion re-
quirement. The similar RFS and OS in both groups be-
fore and after PSM are consistent with results in
previous studies [4,9,31], indicating that HCC patients
may still benefit from HR regardless of presence of PHT.
This result is also confirmed by multivariate analysis in-
dicating that only lower MELD score, an advanced stage
of tumor and ineffective management of intraoperative
hemorrhage were prognostic factors for overall survival.
With the refinement of patient selection and improve-
ment in surgical management, especially in manage-
ment of intraoperative hemorrhage, HCC patients withclinically diagnosed PHT can achieve acceptable postop-
erative outcome.
Although the 2012 EASL-EORTC Clinical Practice
Guidelines [12] mention that portal hypertension is a valid
prognostic factor in patients undergoing resection in Asia
[10], most cirrhotic patients in these studies have an etio-
logical background of hepatitis C virus (HCV) and alcohol,
rather than HBV (Table 5). In contrast, HBV is the largest
attributable factor (60%) for HCC [32] in Africa and East
Asia, while in Europe 60–70% of cases can be attributed
to the HCV infection [33]. Consideration should therefore
be given to etiological differences in these regions and
their influence on postoperative outcome should be evalu-
ated. Importantly, post-resection mortality has been re-
ported to be significantly higher in alcoholic and HCV
patients than in HBV patients [34], and an improved rate
of OS has been observed in HBV HCC patients compared
with those with HCV [35]. Indeed, to date, few studies
have been conducted in HBV prevalent regions that
Table 4 Univariate and multivariate analysis of predictive factors of overall survival after PSM
Variables Univariate analysis Multivariate analysis
χ2 P RR 95% CI P
Age > 65y (Yes : No) 0.001 0.982
Gender (Male : Female) 1.945 0.163
Etiology of cirrhosis (HBV: non-HBV) 0.001 0.976
ALB (<35 : >35) 0.018 0.892
INR (<1.2 : >1.2) 2.930 0.087
Child-Pugh classification (A : B) 1.994 0.158
MELD (<9 : >9) 3.480 0.065 2.113 1.242-3.593 0.006
PHT (Yes : No) 0.660 0.417
Number of tumor (1 : >1) 10.134 0.001 2.020 1.192-3.424 0.009
Size of tumor (<5 : >5) 5.604 0.018
Vascular invasion (Yes : No) 13.767 <0.001 2.289 1.137-4.612 0.020
Adjacent tissues invasion (Yes : No) 11.552 0.001 2.549 1.372-4.735 0.003
Intraoperative haemorrhage >400 ml (Yes : No) 8.770 0.003 1.849 1.027-3.330 0.041
Extent of hepatectomy (1 : >1) 0.443 0.506
Intraoperative Transfusion (Yes : No) 2.565 0.109
Pringle maneuver (Yes : No) 0.287 0.592
Lymphatic metastasis is not included in analysis because there is only 1 case in 118 patients after matching.
He et al. BMC Cancer  (2015) 15:263 Page 9 of 11support recommendations of the guidelines on this issue
[6, 7], with one of these pointing out that even if PHT is a
powerful prognostic factor, patients with a single tumor
and absence of gross vascular invasion may still experience
a survival benefit from HR [7]. We therefore surmise that
the recommendation made in the guidelines that PHT
should be a contraindication for HR is not appropriate for
all patients in these regions. The current study, to the best
of our knowledge, is the first study demonstrating that
clinically significant PHT is neither a prognostic factor forTable 5 Review of etiological characteristics of patient cohort
Study (year) Patients Etiology
HBV
Nagasue et al. (1999) [36] 63 16 (25.40%)
Llovet, J. M. (1999) [3] 164 17 (10.37%)
Ripoll, C. (2005) [37] 393 35(8.9%)
An M (2006) [6] 142 115 (80.99%)
Capussotti, L. (2006) [8] 217 43 (19.82%)
Minagawa, M. (2007) [5] 13566 2682 (19.77%)
Kawano, Y. (2008) [9] 134 29 (21.64%)
Ishizawa T (2008) [10] 386 75 (19.43%)
Cucchetti, A. (2009) [4] 241 37 (15.35%)
Choi, G. H. (2011) [7] 100 77 (77%)
Boleslawski, E. (2012) [25] 40 5 (12.5%)
Santambrogio, R. (2013) [11] 223 38 (17.04%)
*Others etiologies include HBV + HCV, hemochromatosis, metabolic, cholestasis andpostoperative complication nor for overall survival after
HR in a hepatitis B virus prevalent region.
Nevertheless, our study has several limitations. All pa-
tient data were obtained from a single institution. Thus,
multiple-center studies will be necessary to validate our
conclusions. In addition, PHT in this retrospective study
was indirectly diagnosed by clinical criteria so we are
still not able to address the role of HVPG measurement
as the diagnostic criterion for PHT in HCC patients with
HBV cirrhosis.s in previous studies of PHT
HCV Alcohol Others*
29 (46.03%) — 18 (28.57%)
122 (74.39%) 16 (9.76%) 9 (5.49%)
142(36.1%) 172(43.8%) 44 (11.20%)
6 (4.23%) — 21 (14.79%)
105 (48.39%) 62 (28.57%) 7 (3.23%)
9025 (66.53%) 3063 (22.58%) —
75 (55.97%) — 30 (22.39%)
251 (65.03%) —
162 (67.22%) — 42 (17.43%)
— — —
30 (75%) 5 (12.5%)
135 (60.54%) — 50 (22.41%)
unknown factors.
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In conclusion, with respect to postoperative complication,
liver decompensation, RFS and OS, clinically significant
PHT should not be regarded as contraindication for HR
because HCC patients in HBV prevalent region can still
benefit from surgery if preoperative liver function is
well-preserved and intraoperative hemorrhage is under
control.
Abbreviations
HCC: Hepatocellular carcinoma); PHT: Portal hypertension; PSM: Propensity
score matching; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ALB: Albumin;
TBIL: Total bilirubin; ALT: Alanine aminotransferase; AST: Aspartate
aminotransferase; WBC: White blood cell; RBC: Red blood cell; BUN: Blood
urea nitrogen; PT: Prothrombin time; APTT: Activated partial thromboplastin
time); INR: International normalized ratio; MELD: Model for end stage liver
disease.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
WH performed the statistical analysis, interpreted the results and drafted the
manuscript. QLZ drafted and revised the manuscript. YZ and MXC
contributed to study design and intellectual content. JXS and JLQ helped to
performed the statistical analysis and interpreted the data. MC, RHZ, YDL,
QJL and XQW acquired the data. BKL contributed to study design and
critically revised the manuscript. YFY conceived of the study, critically revised
and approved the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
This work was supported by grants from the National Natural Science
Foundation of China (No. 81172344, 81372571, and 81101863), the Key
Project of Education Department of Guangdong Province (No. CXZD1133),
Guangdong Department of Science & Technology Translational Medicine
Center grant 2011A080300002, the Sun Yat-Sen University Clinical Research
5010 Program (No. 2012010).
Author details
1State Key Laboratory of Oncology in South China and Collaborative
Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer
Center, Guangzhou, China. 2Department of Hepatobiliary Oncology, Sun
Yat-Sen University Cancer Center, Guangzhou, China. 3Department of
Medical Imaging and Interventional Center, Sun Yat-Sen University Cancer
Center, Guangzhou, China. 4Department of Surgery, People’s Hospital of
Jiangxi Province, Nanchang, China. 5Department of Ultrasound, Sun Yat-Sen
University Cancer Center, Guangzhou, China.
Received: 5 December 2014 Accepted: 27 March 2015
References
1. IARC. Available from: http://www-dep.iarc.fr: [accessed November 1st, 2011].
2. Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, et al. Surgical
resection of hepatocellular carcinoma in cirrhotic patients: prognostic value
of preoperative portal pressure. Gastroenterology. 1996;111:1018–22.
3. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment
for early hepatocellular carcinoma: resection versus transplantation.
Hepatology. 1999;30:1434–40.
4. Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, Ramacciato G,
et al. Is portal hypertension a contraindication to hepatic resection? Ann
Surg. 2009;250:922–8.
5. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of
hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC
TNM systems in a cohort of 13,772 patients in Japan. Ann Surg.
2007;245:909–22.
6. An M, Park JW, Shin JA, Choi JI, Kim TH, Kim SH, et al. [The adverse effect of
indirectly diagnosed portal hypertension on the complications andprognosis after hepatic resection of hepatocellular carcinoma]. Korean J
Hepatol. 2006;12:553–61.
7. Choi GH, Park JY, Hwang HK, Kim DH, Kang CM, Choi JS, et al. Predictive
factors for long-term survival in patients with clinically significant portal
hypertension following resection of hepatocellular carcinoma. Liver Int.
2011;31:485–93.
8. Capussotti L, Ferrero A, Vigano L, Muratore A, Polastri R, Bouzari H. Portal
hypertension: contraindication to liver surgery? World J Surg. 2006;30:992–9.
9. Kawano Y, Sasaki A, Kai S, Endo Y, Iwaki K, Uchida H, et al. Short- and
long-term outcomes after hepatic resection for hepatocellular carcinoma
with concomitant esophageal varices in patients with cirrhosis. Ann Surg
Oncol. 2008;15:1670–6.
10. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, et al. Neither
multiple tumors nor portal hypertension are surgical contraindications for
hepatocellular carcinoma. Gastroenterology. 2008;134:1908–16.
11. Santambrogio R, Kluger MD, Costa M, Belli A, Barabino M, Laurent A, et al.
Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh's
A cirrhosis: is clinical evidence of portal hypertension a contraindication?
HPB (Oxford). 2013;15:78–84.
12. European Association For The Study Of The L, European Organisation For R,
Treatment Of C. EASL-EORTC clinical practice guidelines: management of
hepatocellular carcinoma. J Hepatol. 2012;56:908–43.
13. Qamar AA, Grace ND, Groszmann RJ, Garcia-Tsao G, Bosch J, Burroughs AK,
et al. Incidence, prevalence, and clinical significance of abnormal
hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol.
2009;7:689–95.
14. Berzigotti A, Gilabert R, Abraldes JG, Nicolau C, Bru C, Bosch J, et al.
Noninvasive prediction of clinically significant portal hypertension and
esophageal varices in patients with compensated liver cirrhosis. Am J
Gastroenterol. 2008;103:1159–67.
15. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC
staging classification. Semin Liver Dis. 1999;19:329–38.
16. Bayraktar Y, Balkanci F, Uzunalimoglu B, Gokoz A, Koseoglu T, Batman F,
et al. Is portal hypertension due to liver cirrhosis a major factor in the
development of portal hypertensive gastropathy? Am J Gastroenterol.
1996;91:554–8.
17. Pagliaro L, Spina L. The italian programme on liver cirrhosis. Ital J
Gastroenterol. 1987;19:295–7.
18. Li B, Yuan Y, Chen G, He L, Zhang Y, Li J, et al. Application of tumor-node-
metastasis staging 2002 version in locally advanced hepatocellular carcinoma:
is it predictive of surgical outcome? BMC Cancer. 2010;10:535.
19. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al.
The Clavien-Dindo classification of surgical complications: five-year experience.
Ann Surg. 2009;250:187–96.
20. Balzan S, Belghiti J, Farges O, Ogata S, Sauvanet A, Delefosse D, et al. The "50-
50 criteria" on postoperative day 5: an accurate predictor of liver failure and
death after hepatectomy. Ann Surg. 2005;242:824–8. discussion 828–829.
21. Hill J. Discussion of research using propensity-score matching: comments
on 'A critical appraisal of propensity-score matching in the medical literature
between 1996 and 2003' by Peter Austin, Statistics in Medicine. Stat Med.
2008;27:2055–61. discussion 2066–2059.
22. Stuart EA. Matching methods for causal inference: a review and a look
forward. Stat Sci. 2010;25:1–21.
23. Austin PC. Optimal caliper widths for propensity-score matching when
estimating differences in means and differences in proportions in
observational studies. Pharm Stat. 2011;10:150–61.
24. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK,
et al. Clinical management of hepatocellular carcinoma. Conclusions of the
Barcelona-2000 EASL conference. European Association for the Study of the
Liver. J Hepatol. 2001;35:421–30.
25. Boleslawski E, Petrovai G, Truant S, Dharancy S, Duhamel A, Salleron J,
et al. Hepatic venous pressure gradient in the assessment of portal
hypertension before liver resection in patients with cirrhosis. Br J Surg.
2012;99:855–63.
26. Stremitzer S, Tamandl D, Kaczirek K, Maresch J, Abbasov B, Payer BA, et al.
Value of hepatic venous pressure gradient measurement before liver
resection for hepatocellular carcinoma. Br J Surg. 2011;98:1752–8.
27. Ruzzenente A, Valdegamberi A, Campagnaro T, Conci S, Pachera S, Iacono
C, et al. Hepatocellular carcinoma in cirrhotic patients with portal
hypertension: is liver resection always contraindicated? World J
Gastroenterol. 2011;17:5083–8.
He et al. BMC Cancer  (2015) 15:263 Page 11 of 1128. Liu L, Wang Z, Jiang S, Shao B, Liu J, Zhang S, et al. Perioperative
allogenenic blood transfusion is associated with worse clinical outcomes for
hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8:e64261.
29. Romano F, Garancini M, Uggeri F, Degrate L, Nespoli L, Gianotti L, Nespoli A,
Uggeri F: Bleeding in Hepatic Surgery: Sorting through Methods to Prevent
It. HPB surgery : a world journal of hepatic, pancreatic and biliary surgery
2012, 2012:169351.
30. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, et al.
Improvement in perioperative outcome after hepatic resection: analysis of
1,803 consecutive cases over the past decade. Ann Surg. 2002;236:397–406.
discussion 406–397.
31. Giannini EG, Savarino V, Farinati F, Ciccarese F, Rapaccini G, Marco MD, et al.
Influence of clinically significant portal hypertension on survival after
hepatic resection for hepatocellular carcinoma in cirrhotic patients. Liver Int.
2013;33:1594–600.
32. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer
J Clin. 2005;55:74–108.
33. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet.
2003;362:1907–17.
34. Belghiti J, Regimbeau JM, Durand F, Kianmanesh AR, Dondero F, Terris B,
et al. Resection of hepatocellular carcinoma: a European experience on 328
cases. Hepatogastroenterology. 2002;49:41–6.
35. Kao WY, Su CW, Chau GY, Lui WY, Wu CW, Wu JC. A comparison of prognosis
between patients with hepatitis B and C virus-related hepatocellular carcinoma
undergoing resection surgery. World J Surg. 2011;35:858–67.
36. Nagasue N, Kohno H, Tachibana M, Yamanoi A, Ohmori H, El-Assal ON.
Prognostic factors after hepatic resection for hepatocellular carcinoma
associated with Child-Turcotte class B and C cirrhosis. Ann Surgery.
1999;229:84–90.
37. Ripoll C, Banares R, Rincon D, Catalina MV, Lo Iacono O, Salcedo M, et al.
Influence of hepatic venous pressure gradient on the prediction of survival
of patients with cirrhosis in the MELD Era. Hepatology. 2005;42:793–801.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
